ImpediMed

ImpediMed EPS Growth

The EPS Growth of ImpediMed (IPD.AX) as of Nov 11, 2026 is 2.73 %. In the previous year, EPS Growth was -28.68 % — a change of -109.53% (higher).

EPS Growth

2.73 %

YoY

-109.53%

Last updated:

EPS Growth of ImpediMed is 2026 2.73 % . EPS Growth of ImpediMed was 2025 -28.68 % . It decreases by -109.53% higher compared to the previous year.

The ImpediMed EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2019
32.12 AUD
Jan 1, 2020
58.40 AUD
Jan 1, 2021
35.55 AUD
Jan 1, 2022
14.73 AUD
Jan 1, 2023
24.28 AUD
Jan 1, 2024
-5.10 AUD
Jan 1, 2025
-28.68 AUD
Jan 1, 2026
2.73 AUD
The ImpediMed EPS Growth history
YEAREPS GrowthYoY
2.73 %-109.53%
-28.68 %+462.07%
-5.10 %-121.01%
24.28 %+64.82%
14.73 %-58.55%
35.55 %-39.13%
58.40 %+81.84%
32.12 %+1,464.62%
2.05 %-135.72%
-5.75 %-84.73%
-37.63 %-31.79%
-55.17 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

EPS Growth of ImpediMed is 2.73 % in 2026.

On Eulerpool you can find the complete historical development of EPS Growth ImpediMed since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's ImpediMed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — ImpediMed

All Key Metrics — ImpediMed